Berfin Gülave
PhD candidate
- Name
- B. Gülave
- Telephone
- +31 71 527 6071
- b.gulave@lacdr.leidenuniv.nl
Berfin Gülave studied the master Biomedical Sciences (Neurobiology) at the University of Amsterdam from 2015 to 2017, followed by a second master Drug Innovation at Utrecht University from 2017 to 2019. Since January 2020, she started her PhD project in the H2020 consortium QSPainRelief. The aim of this consortium is to develop a novel in silico modelling platform to evaluate new combinations of existing central nervous system (CNS) drugs with respect to improved analgesia and reduced sedation, cognitive impairment, and abuse liability. The focus of her project will be on predicting the CNS distribution of pain relieving drugs in health and in chronic pain conditions. To this end, data on drug specific properties and species specific characteristics in health and chronic pain will be collected and used in mathematical models for predictions on CNS distribution.
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Budda D., Gülave B., Hasselt J.G.C. van & Lange E.C.M. de (2024), Non‐linear blood–brain barrier transport and dosing strategies influence receptor occupancy ratios of morphine and its metabolites in pain matrix, British Journal of Pharmacology 181(20): 3856-3868.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2024), Corrigendum to “Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?” , European Journal of Pharmaceutical Sciences 196: 106736.
- Saleh M.A.A.E.W., Gülave B., Campagne O., Stewart C.F., Elassaiss J. & Lange E.C.M. de (2023), Using the LeiCNS-PK3.0 physiologically-based pharmacokinetic model to predict brain extracellular fluid pharmacokinetics in mice, Pharmaceutical Research 40: 2555-2566.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2023), Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?, European Journal of Pharmaceutical Sciences 187: 106482.
- Saleh M.A.A.E.W., Hirasawa M., Sun M., Berfin G., Elassaiss J. & Lange E.C.M. de (2022), The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells, European Journal of Pharmaceutical Sciences 181: 106345.
- Gülave B., Hew M.N., Groot J.S. de, Rodwell L., Teerenstra S. & Fabriek B.O. (2021), High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors, ESMO Open 6(3): 100107.
- Brink W.J. van den, Wong Y.C., Gülave B., Graaf P.H. van der & Lange E.C.M. de (2017), Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling, AAPS Journal 19(1): 274–285.